Last reviewed · How we verify

Humulin (insulin)

Eli Lilly · FDA-approved approved Quality 60/100

Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels.

Humulin is a recombinant human insulin developed by Eli Lilly and Company, initially approved by the FDA in 1982 for the treatment of diabetes mellitus type 1 and type 2. It works by targeting the tyrosine-protein kinase Lck, a key enzyme involved in glucose metabolism. As a recombinant human insulin, Humulin is a biologic drug that mimics the natural insulin produced by the human body. It is currently owned by Eli Lilly and Company, and its commercial status is proprietary. Key safety considerations include the risk of hypoglycemia and allergic reactions.

At a glance

Generic nameinsulin
SponsorEli Lilly
Drug classInsulin Analog [EPC]
TargetTyrosine-protein kinase Lck
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1982

Mechanism of action

The primary activity of insulin, including NOVOLIN is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: